Medication info
DS Tablet 160mg (Valsartan)

DS Tablet 160mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Poonglim Pharmaceutical Co., Ltd.
Appearance
Oval film-coated tablet with an orange color that has a grayish hue
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201505158 · Approved 2015.07.30 · Insurance code 649001430

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased up to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administering concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Poonglim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medicine is used for the treatment of essential hypertension and is effective for heart failure patients who are intolerant to ACE inhibitors (NYHA class II to IV). Additionally, it helps reduce the risk of death in patients with stable myocardial infarction accompanying left ventricular failure or systolic dysfunction. It is used for improving various cardiovascular diseases.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased up to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administering concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Precautions

This medicine can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. Therefore, if pregnancy is confirmed, it should be stopped immediately. This medicine should not be used in women who are pregnant, possibly pregnant, or breastfeeding. It is safer not to administer this medicine to patients with severe liver impairment, cirrhosis, or biliary obstruction. Patients with a history of angioedema or who have experienced angioedema while taking ACE inhibitors or angiotensin II receptor antagonists should not use this medicine. This medicine is not administered to patients with severely impaired kidney function, hyperaldosteronism, or diabetic patients with certain kidney disorders. Elderly patients or those with hyperkalemia, and patients with mild to moderate liver dysfunction should be administered the medicine with caution, as dosage adjustments may be necessary. Patients with cardiovascular disease or dehydration, and pre-operative patients should be closely monitored when administering this medicine. This medicine can suddenly lower blood pressure; thus, special caution is needed when taking it for the first time. If symptoms of hypotension occur, consult a doctor immediately. Interactions may occur when taken with other antihypertensives or diuretics, so it should be taken according to a doctor's instructions. When combined with potassium-sparing diuretics or potassium supplements, there is a risk of increased serum potassium levels, thus regular blood tests are necessary. Regular checks of liver function, kidney function, electrolyte levels, etc. should be performed to ensure there are no abnormalities during the course of taking this medicine. Dizziness or drowsiness may occur; therefore, caution is needed when driving or handling machinery. Safety has not been established in children and adolescents, so use is not recommended. In case of overdose, severe hypotension or decreased consciousness may occur, and immediate emergency care is required. This medicine should be kept out of reach of children and should not be transferred to another container.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine is sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it should be kept in a cool place where the temperature is below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Oval film-coated tablet with an orange color that has a grayish hue

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.